



## OPEN ACCESS

## EDITED BY

Tao Wang,  
Shanghai Jiao Tong University, China

## REVIEWED BY

Wen-Hao Xu,  
Fudan University, China  
Jianfeng Yang,  
Shanghai University of Traditional Chinese  
Medicine, China

## \*CORRESPONDENCE

Fangjian Zhou

✉ zhoufj@sysucc.org.cn  
Yonghong Li

✉ liyongh@sysucc.org.cn  
Yulu Peng

✉ pengyl1@sysucc.org.cn

<sup>†</sup>These authors have contributed  
equally to this work and share  
first authorship

RECEIVED 14 March 2023

ACCEPTED 21 April 2023

PUBLISHED 08 May 2023

## CITATION

Li Z, Huang Y, Zhao D, Luo X, Wu Z,  
Zheng X, Xie Y, Liu Y, Wu J, Peng Y, Li Y  
and Zhou F (2023) Development and  
internal validation of a novel nomogram for  
predicting lymph node invasion for  
prostate cancer patients undergoing  
extended pelvic lymph node dissection.  
*Front. Oncol.* 13:1186319.  
doi: 10.3389/fonc.2023.1186319

## COPYRIGHT

© 2023 Li, Huang, Zhao, Luo, Wu, Zheng,  
Xie, Liu, Wu, Peng, Li and Zhou. This is an  
open-access article distributed under the  
terms of the [Creative Commons Attribution  
License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or  
reproduction in other forums is permitted,  
provided the original author(s) and the  
copyright owner(s) are credited and that  
the original publication in this journal is  
cited, in accordance with accepted  
academic practice. No use, distribution or  
reproduction is permitted which does not  
comply with these terms.

# Development and internal validation of a novel nomogram for predicting lymph node invasion for prostate cancer patients undergoing extended pelvic lymph node dissection

Zhen Li<sup>1,2†</sup>, Yixin Huang<sup>1,2†</sup>, Diwei Zhao<sup>1,2†</sup>, Xin Luo<sup>1,2†</sup>,  
Zeshen Wu<sup>3</sup>, Xinyi Zheng<sup>4</sup>, Ye Xie<sup>4</sup>, Yixuan Liu<sup>4</sup>, Jianwei Wu<sup>5</sup>,  
Yulu Peng<sup>1,2\*</sup>, Yonghong Li<sup>1,2\*</sup> and Fangjian Zhou<sup>1,2\*</sup>

<sup>1</sup>Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China, <sup>2</sup>State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China, <sup>3</sup>Department of Urology, Huazhong University of Science and Technology Union Shenzhen Hospital (Nanshan Hospital), Shenzhen, China, <sup>4</sup>Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China, <sup>5</sup>School of Clinical Medicine, Tianjin Medical University, Tianjin, China

**Background:** Few studies have focused on the performance of Briganti 2012, Briganti 2017 and MSKCC nomograms in the Chinese population in assessing the risk of lymph node invasion(LNI) in prostate cancer(PCa) patients and identifying patients suitable for extended pelvic lymph node dissection(ePLND). We aimed to develop and validate a novel nomogram based on Chinese PCa patients treated with radical prostatectomy(RP) and ePLND for predicting LNI.

**Methods:** We retrospectively retrieved clinical data of 631 patients with localized PCa receiving RP and ePLND at a Chinese single tertiary referral center. All patients had detailed biopsy information from experienced uropathologist. Multivariate logistic-regression analyses were performed to identify independent factors associated with LNI. The discrimination accuracy and net-benefit of models were quantified using the area under curve(AUC) and Decision curve analysis (DCA).The nonparametric bootstrapping were used to internal validation.

**Results:** A total of 194(30.7%) patients had LNI. The median number of removed lymph nodes was 13(range, 11-18). In univariable analysis, preoperative prostate-specific antigen(PSA), clinical stage, biopsy Gleason grade group, maximum percentage of single core involvement with highest-grade PCa, percentage of positive cores, percentage of positive cores with highest-grade PCa and percentage of cores with clinically significant cancer on systematic biopsy differed significantly. The multivariable model that included preoperative PSA, clinical stage, biopsy Gleason grade group, maximum percentage of single core involvement with highest-grade PCa and percentage of cores with clinically significant cancer on systematic biopsy represented the basis for the novel nomogram. Based on a 12% cutoff, our results showed that 189(30%) patients could have avoided ePLND while only 9(4.8%) had LNI missing ePLND. Our

proposed model achieved the highest AUC (proposed model vs Briganti 2012 vs Briganti 2017 vs MSKCC model: 0.83 vs 0.8 vs 0.8 vs 0.8, respectively) and highest net-benefit *via* DCA in the Chinese cohort compared with previous nomograms. In internal validation of proposed nomogram, all variables had a percent inclusion greater than 50%.

**Conclusion:** We developed and validated a nomogram predicting the risk of LNI based on Chinese PCa patients, which demonstrated superior performance compared with previous nomograms.

#### KEYWORDS

Chinese population, lymph node invasion, nomogram, prostate cancer, pelvic lymph node dissection

## 1 Introduction

Pelvic lymph node dissection (PLND) is routinely performed in patients undergoing prostatectomy for localized prostate cancer (Pca), and the status of pathologically confirmed pelvic lymph node invasion (PLNI) determines the extent of radical prostatectomy (RP) (1). Following the publication of a large sample retrospective clinical report that indicated RP improved the survival of patients with pathologically confirmed PLNI (2), RP has been routinely performed in patients clinically diagnosed with localized prostate cancer regardless of LNI. However, PLND could have been overperformed in the contemporary era because the potential LNI risk in patients with low-risk localized prostate cancer was very low. Even in patients with intermediate and high-risk prostate cancer, most PLND could have been unnecessary due to the low rate of pathologically confirmed LNI, ranging from 8.3% to 12% (3–5).

To avoid unnecessary PLND and identify candidates with LNI for PLND, several nomograms were developed based on patients' characteristics, such as preoperative prostate-specific antigen (PSA), clinical T stage, and Gleason grade of prostate biopsy (3, 5, 6). Although these nomograms were associated with good performance and underwent external validation (7, 8), they were developed on data from European or American patients. Although the incidence of prostate cancer is much lower in China compared with Western countries, the proportion of patients with metastatic prostate cancer in China is comparatively much higher (4, 9). However, till present, the performance of these published nomograms has not been externally validated in Chinese prostate cancer patients. Further, if their performance is unsatisfactory, a novel nomogram based on clinical characteristics and prostate biopsy pathology of Chinese prostate cancer patients would be required to estimate the risk of LNI.

**Abbreviations:** LNI, lymph node invasion; PLNI, pelvic lymph node invasion; PCa, prostate cancer; PLND, pelvic lymph node dissection; ePLND, extended pelvic lymph node dissection; AUC, area under the curve; RP, radical prostatectomy; DCA, decision curve analysis; PSA, prostate-specific antigen; IQR, interquartile range.

In this present study, we determined the clinical performance of three existing nomograms, the Briganti 2012, Briganti 2017 and MSKCC (3, 5, 6), in predicting the risk of LNI using a cohort of Chinese prostate cancer patients, then constructed and internally validated a nomogram specifically designed for Chinese prostate cancer patients.

## 2 Patient and methods

### 2.1 Population source and ePLND

With the approval of the institutional review board of our institution, the clinical and pathological data of localized PCa patients who underwent RP and ePLND at the Sun Yat-sen University Cancer Center (SYSUCC, Guangzhou, China) from 2017 to 2021 were retrieved. Patients were excluded if they had received neoadjuvant hormonal therapy. The physician conducted a ultrasound-guided systematic prostate biopsy in accordance with the requirements of section 5.2.7.1.1 of the 2022 EAU guidelines. An experienced uropathologist reviewed all prostate biopsy specimens from the patients.

RP and ePLND were performed by two experienced surgeons (FJ Zhou and YH Li). The ePLND spectrum included the obturator, external iliac, bilateral internal iliac, and common iliac (eight fields) area. The caudal border of ePLND was the deep circumflex vein and the femoral canal, the cranial border was the ureter crossing over the common iliac artery, the lateral border was the genitofemoral nerve, and the medial border was the vesical fat. All fibrofatty tissues along the external iliac vein and within the obturator fossa were removed for harvesting lymph nodes. Lymph nodes along, medial and lateral to the internal iliac vessels were dissected (10). All lymph nodes were then sent for pathological examination in multiple packages according to different surgical fields (3, 11).

### 2.2 Covariates and endpoint

Preoperative PSA, clinical T stage assessed by the attending urologist with extensive experience according to the 2017 American

Joint Committee on Cancer staging system (AJCC), was recorded. A digital rectal examination was performed by the attending urologist as the basis for clinical staging. The prostate biopsy data, including the number of cores taken, Gleason score grade group for each positive core, the percentage of positive cores, the percentage of PCa involvement, the percentage of positive cores with highest-grade PCa, the percentage of cores with clinically significant cancer and the percentage of cancer in cores were also recorded. The modified Gleason scoring system based on the 2005 and 2014 International Society of Urological Pathology consensus conferences was used (12, 13). LNI was defined as metastasis in lymph nodes confirmed by pathology.

## 2.3 Statistical analyses

For categorical variables, descriptive statistics were reported on frequencies and proportions. Continuously coded variables were described by the median and interquartile range (IQR). Chi-square and t-test were used to compare proportions and medians of categorical variables and continuously coded variables, respectively. Univariable logistic regression analyses were performed to assess predictors of LNI. Since Biopsy Gleason grade groups 4 and 5 have a higher degree of malignancy, the Biopsy Gleason grade group was categorized as  $\leq 3$  versus  $\geq 4$ . Similarly, clinical stages were categorized as  $\geq T3$  versus  $\leq T2$ .

Three well-known nomograms, Briganti 2012, Briganti 2017 and MSKCC nomograms (3, 5, 6), were validated using our cohort. Then, we compared the performance of the 3 nomograms with our developed nomogram in terms of predictive accuracy and net clinical benefit by AUC and DCA, respectively.

Five different models predicting LNI were developed based on the results of univariable logistic regression analyses. Preoperative PSA, clinical T stage, and Biopsy Gleason grade group were included in all 5 models. We quantified the predictive accuracy of multivariable models using the receiver operating characteristic-derived area under the curve (AUC). Given that variables, such as percentage of positive cores and percentage of positive cores with highest-grade PCa, would not improve the predictive accuracy, they were not included in our nomogram. Lastly, preoperative PSA, clinical T stage, biopsy Gleason score group, the maximum percentage of single core involvement with highest-grade PCa, and the percentage of cores with clinically significant cancer were used as the basis of our coefficient-based nomogram. Multivariate logistic model regression coefficients were used to generate our proposed nomogram (SYSUCC model) that could predict the probability of LNI for ePLND in the Chinese cohort. The novel nomogram was conducted with 1000 bootstrap resamples to reduce overfitting bias and perform internal validation. A decision curve analysis (DCA) (12) was performed to determine the net benefit associated with the models. The discrimination and DCA were corrected for overfitting using leave-one-out cross-validation.

All statistical tests were performed using the R statistical package v.3.0.2 (R Project for Statistical Computing, [www.r-project.org](http://www.r-project.org)).

All tests were two-sided, with a significance level set at  $p < 0.05$ .

## 3 Result

### 3.1 Baseline characteristics

A total of 631 PCa patients were eligible for this study, and their descriptive statistics are summarized in Table 1. LNI was identified in 194 (30.7%) patients. The median (IQR) number of lymph nodes retrieved was 13 (range, 11-18). Preoperative PSA, clinical T stage, Biopsy Gleason grade group, percentage of positive cores, percentage of positive cores with highest-grade PCa, and percentage of cores with clinically significant cancer on systematic biopsy differed significantly between pN0 and pN1 patients ( $p < 0.001$ ; Table 1). There were no significant differences in age at surgery and the number of biopsy cores between pN0 and pN1 patients ( $p > 0.05$ ; Table 1).

### 3.2 External validation of the Briganti 2012, Briganti 2017 and MSKCC nomograms

External validation of the Briganti 2012 nomogram with a recommended cutoff of 5% revealed that only 1.9% of ePLND needed to be avoided, while 8.3% patients who are not recommended for an ePLND had LNI but missed an ePLND in our cohort. For the Briganti 2017 nomogram with a recommended cutoff of 7%, PLND could be avoided in 7.1% of patients at the cost of missing 6.7% of LNIs in our cohort (Table 2). Our results for the MSKCC nomogram, with a recommended cutoff of 2%, showed that no patient could avoid PLND (Table 2).

### 3.3 Establish a novel nomogram predicting LNI

Based on univariable analyses (Table 3), preoperative PSA, clinical T stage, biopsy Gleason grade group, maximum percentage of single core involvement with highest-grade PCa, percentage of positive cores, percentage of positive cores with highest-grade PCa and percentage of cores with clinically significant cancer on systematic biopsy served as predictors of LNI. On multivariable analyses, preoperative PSA, clinical T stage, and biopsy Gleason score group, maximum percentage of single core involvement with highest-grade PCa, percentage of positive cores, and percentage of cores with clinically significant cancer on systematic biopsy presented independent predictors of LNI (Table 3). When these covariates were fitted in multivariable models, model 5 (including preoperative PSA, clinical T stage, biopsy Gleason grade group, maximum percentage of single core involvement with highest-grade PCa, and percentage of cores with clinically significant cancer on systematic biopsy) demonstrated the highest AUC on internal validation (83%). Therefore, model 5, termed the SYSUCC model, was chosen as the

**TABLE 1** Descriptive statistics of 631 patients with clinically localized prostate cancer (PCa) treated with RP and ePLND from January 2017 to December 2021.

|  | Overall<br>(n=631) | pN <sub>0</sub><br>(n=437) | pN <sub>1</sub><br>(n=194) | P value |
|--|--------------------|----------------------------|----------------------------|---------|
| Age at surgery (yr)<br>Median (IQR)  | 67.0(62.0,72.0)    | 67.0(62.0,72.0)            | 68.0(62.0,71.0)            | 0.936   |
| Preoperative PSA (ng/ml)Median (IQR)   | 23.0 (12.5,48.2)   | 17.6(10.4,31.6)            | 48.2 (22.9,97.3)           | <0.001  |
| DRE(%)   | 224 (35.5)         | 123 (28.1)                 | 101 (52.1)                 | <0.001  |
| Clinical stage (%)   |                    |                            |                            |         |
| ≤T2  | 428 (67.8)         | 335 (76.7)                 | 93 (47.9)                  | <0.001  |
| ≥T3  | 203 (32.2)         | 102 (23.3)                 | 101 (52.1)                 |         |
| <b>Biopsy Gleason grade group (%)</b>  |                    |                            |                            |         |
| 1  | 50 (7.9)           | 46 (10.5)                  | 4 (2.1)                    | <0.001  |
| 2  | 107 (17.0)         | 85 (19.5)                  | 22 (11.3)                  |         |
| 3  | 110 (17.4)         | 86 (19.7)                  | 24 (12.4)                  |         |
| 4  | 190 (30.1)         | 129 (29.5)                 | 61 (31.4)                  |         |
| 5  | 174 (27.6)         | 91 (20.8)                  | 83 (42.8)                  |         |
| No. of cores taken<br>Median (IQR)   | 11 (10,12)         | 11 (10,12)                 | 11 (10,12)                 | 0.109   |
| Percentage of positive cores Median (IQR)  | 50 (20, 83)        | 42 (18, 67)                | 82 (50, 100)               | <0.001  |
| Percentage of positive cores with highest-grade PCa Median (IQR)                         | 27 (10, 50)        | 23 (10, 47)                | 42 (17, 75)                | <0.001  |
| Percentage of cores with clinically significant cancer on systematic biopsy Median (IQR) | 42 (17, 80)        | 33 (10, 58)                | 78 (38, 100)               | <0.001  |
| Maximum percentage of single core involvement with highest-grade PCa                     | 60 (40, 80)        | 50(30, 70)                 | 70 (60, 90)                | <0.001  |
| Surgical margin(%)   | 392 (62.1)         | 245 (56.1)                 | 147 (75.8)                 | <0.001  |
| <b>Surgical technique (%)</b>  |                    |                            |                            |         |
| ORP  | 279 (44.2)         | 153 (35.0)                 | 126 (64.9)                 | <0.001  |
| RARP   | 352 (55.8)         | 284 (65.0)                 | 68 (35.1)                  |         |
| <b>Gleason grade group at final pathology (%)</b>  |                    |                            |                            |         |
| 1  | 22 (3.5)           | 21 (4.8)                   | 1 (0.5)                    | <0.001  |
| 2  | 89 (14.1)          | 79 (18.1)                  | 10 (5.2)                   |         |
| 3  | 139 (22.0)         | 111 (25.4)                 | 28 (14.4)                  |         |
| 4  | 96 (15.2)          | 66 (15.1)                  | 30 (15.5)                  |         |
| 5  | 285 (45.2)         | 160 (36.6)                 | 125 (64.4)                 |         |
| <b>Pathologic stage (%)</b>  |                    |                            |                            |         |
| T2   | 286 (45.3)         | 264 (60.4)                 | 22 (11.3)                  | <0.001  |
| T3a  | 76 (12.0)          | 57 (13.0)                  | 19 (9.8)                   |         |
| T3b  | 227 (36.0)         | 106 (24.3)                 | 121 (62.4)                 |         |
| T4   | 42 (6.7)           | 10 (2.3)                   | 32 (16.5)                  |         |
| Number of removed lymph nodes<br>Median (IQR)  | 13.0 (11.0,18.0)   | 13.0(10.0,18.0)            | 14.0 (12.0, 18.0)          | 0.017   |
| Number of positive lymph nodes<br>Median (IQR)   | 0.0 (0.0, 1.0)     | NA                         | 2.0(1.0, 4.0)              | <0.001  |

IQR, interquartile range; NA, not applicable; ORP, open radical prostatectomy; PSA, prostate-specific antigen; RARP, robot-assisted radical prostatectomy; PCa, prostate cancer; DRE, the digital rectal examination.

TABLE 2 External validation of Briganti 2012, Briganti 2017 and MSKCC nomogram.

| Treatment option                  | ePLND is not recommended according to the cutoff (below cutoff) | Below cutoff without histologic LNI | Below cutoff with histologic LNI | ePLND is recommended according to the cutoff (above cutoff) | Above cutoff without histologic LNI | Above cutoff with histologic LNI |
|-----------------------------------|---|-------------------------------------|----------------------------------|---|-------------------------------------|----------------------------------|
| Briganti 2012 nomogram, 5% cutoff | 12(1.9)   | 11(91.7)                            | 1 (8.3)                          | 619 (98.1)  | 426 (68.8)                          | 193 (31.2)                       |
| Briganti 2017 nomogram, 7% cutoff | 45(7.1)   | 42(93.3)                            | 3(6.7)                           | 586(92.9)   | 395 (67.4)                          | 191 (32.6)                       |
| MSKCC nomogram, 2% cutoff         | 0(0)  | 0(0)                                | 0(0)                             | 631(100)  | 437(69.3)                           | 194(30.7)                        |

LNI, lymph node invasion; ePLND, extended pelvic lymph node dissection.

novel nomogram for predicting LNI in this study. The multivariate influence of each variable on the probability of LNI is visually shown in Figure 1 as a nomogram. Supplementary Table 1 illustrates the error and predictive accuracy using the novel nomogram for predicting the risk of LNI when choosing different cutoffs. Using a 12% cutoff, ePLND was estimated to be avoided in 189 of 631 (30%) patients at the cost of missing 4.8% of LNI in patients who harbored LNI. (Supplementary Table 1).

### 3.4 Comparison of the novel nomogram with currently available models

The SYSUCC model achieved the highest AUC in our cohort of patients compared with the Briganti 2012, Briganti 2017 and MSKCC models (0.83 vs 0.8 vs 0.8 vs 0.8 for the novel vs Briganti 2012 vs Briganti 2017 vs MSKCC model, respectively) (Figure 2A). Compared with the Briganti 2012, Briganti 2017 and MSKCC models, the DCA

TABLE 3 Uni- and multivariable logistic regression analyses assessing predicting the presence of lymph node invasion in 631 patients treated with radical prostatectomy and extended pelvic lymph node dissection.

|   | Univariable analyses |         | Model 1 Multivariable analyses |         | Model 2 Multivariable analyses |         | Model 3 Multivariable analyses |         | Model 4 Multivariable analyses |         | Model 5 Multivariable analyses |         |
|---|----------------------|---------|--------------------------------|---------|--------------------------------|---------|--------------------------------|---------|--------------------------------|---------|--------------------------------|---------|
|   | OR (95% CI)          | p value | OR (95% CI)                    | p value | OR (95% CI)                    | p value | OR (95% CI)                    | p value | OR (95% CI)                    | p value | OR (95% CI)                    | p value |
| Preoperative PSA  | 1.03 (1.02-1.04)     | <0.001  | 1.03 (1.02-1.03)               | <0.001  | 1.02 (1.02-1.03)               | <0.001  | 1.02 (1.02-1.03)               | <0.001  | 1.02 (1.02-1.03)               | <0.001  | 1.02 (1.02-1.03)               | <0.001  |
| Clinical stage(≥T3 vs ≤T2)  | 3.57 (2.49-5.10)     | <0.001  | 2.59 (1.74-3.84)               | <0.001  | 2.29 (1.52-3.45)               | <0.001  | 2.23 (1.48-3.37)               | <0.001  | 2.25 (1.49-3.39)               | <0.001  | 2.17 (1.43-3.29)               | <0.001  |
| Biopsy Gleason grade group (1-3 vs 4-5)                                     | 2.72 (1.88-3.93)     | <0.001  | 2.19 (1.45-3.30)               | <0.001  | 1.81 (1.18-2.79)               | 0.007   | 1.72 (1.11-2.65)               | 0.015   | 1.81 (1.18-2.78)               | 0.007   | 1.58 (1.01-2.45)               | 0.044   |
| Maximum percentage of single core involvement with highest-grade PCa        | 1.04 (1.03-1.05)     | <0.001  | -                              | -       | 1.03 (1.02-1.04)               | <0.001  | 1.03 (1.02-1.04)               | <0.001  | 1.03 (1.02-1.04)               | <0.001  | 1.03 (1.02-1.04)               | <0.001  |
| Percentage of positive cores  | 10.45 (5.90-18.54)   | <0.001  | -                              | -       | -                              | -       | 2.24 (1.14-4.38)               | 0.019   | -                              | -       | -                              | -       |
| Percentage of positive cores with highest-grade PCa                         | 5.45 (3.05-9.75)     | <0.001  | -                              | -       | -                              | -       | -                              | -       | 1.57 (0.78-3.16)               | 0.203   | -                              | -       |
| Percentage of cores with clinically significant cancer on systematic biopsy | 12.61 (7.23-22.00)   | <0.001  | -                              | -       | -                              | -       | -                              | -       | -                              | -       | 2.98 (1.53-5.81)               | 0.001   |
| AUC of multivariable models   | -                    | -       | 0.79                           | -       | 0.82                           | -       | 0.82                           | -       | 0.82                           | -       | 0.83                           | -       |

PCa, prostate cancer; AUC, area under the curve; PSA, prostate-specific antigen; OR, odds ratio.

graphically depicted that the SYSUCC nomogram could improve the clinical risk prediction and had the highest clinical net benefit for LNI threshold probabilities <60% approximately (Figure 2B).


At the cutoff of 12%, the SYSUCC nomogram demonstrated the highest ePLND sparing percentage and the lowest percentage of LNIs missing compared with the Briganti 2012, Briganti 2017 and MSKCC nomograms (Table 4).

### 3.5 Bootstrap validation


All variables had a percent inclusion greater than 50%, which confirmed the stability of these variables in the final model. Besides, the risk ratio with a 95% confidence interval was estimated for each covariate (Supplementary Table 2).

## 4 Discussion

PCa patients harbor LNI are at a high risk of poor survival (14, 15). PLND is still the gold standard of nodal staging for detecting LNI in PCa (16). However, expanding the scope of surgery increases the risk of complications (17). Therefore, several clinical guidelines recommend using predictive models developed by clinical data of patients performing ePLND, such as the Briganti 2012, Briganti 2017 and MSKCC nomograms, to assess the risk of LNI in PCa patients and determine who should be considered for ePLND during RP (3, 5, 6). Although these models have high predictive accuracy during internal and external validation in European or American cohorts, their performance in Chinese patients remained undetermined. Given the influence of ethnic differences in PCa, we hypothesized that these models would not be suitable for Chinese



**FIGURE 1**  
The SYSUCC nomogram predicting the probability of lymph node invasion (LNI) in patients undergoing expand pelvic lymph node dissection (ePLND). PSA, prostate-specific antigen; PCa, prostate cancer.



**FIGURE 2**  
(A) Receiver operating characteristic curve for the four prediction models: the SYSUCC model, the Briganti model of 2012, the Briganti model of 2017, the MSKCC model. (B) Decision curve analysis (DCA) demonstrating the net benefit associated with use of the SYSUCC model for detection of lymph node invasion (LNI) in comparison to currently three classical models (Briganti 2012, Briganti 2017, and MSKCC model).



TABLE 4 Clinical implications according to treatment option (SYSUCC nomogram vs Briganti2012 nomogram vs Briganti2017 nomogram vs MSKCC nomogram).

| Treatment option                   | ePLND is not recommended according to the cutoff (below cutoff) | Below cutoff without histologic LNI | Below cutoff with histologic LNI | ePLND is recommended according to the cutoff (above cutoff) | Above cutoff without histologic LNI | Above cutoff with histologic LNI |
|------------------------------------|---|-------------------------------------|----------------------------------|---|-------------------------------------|----------------------------------|
| SYSUCC nomogram, 12% cutoff        | 189 (30.0)  | 180 (95.2)                          | 9 (4.8)                          | 442 (70.0)  | 257 (58.1)                          | 185 (41.9)                       |
| Briganti 2012 nomogram, 12% cutoff | 158(25.0)   | 149(94.3)                           | 9 (5.7)                          | 473 (75.0)  | 288 (60.9)                          | 185 (39.1)                       |
| Briganti 2017 nomogram, 12% cutoff | 139(22.0)   | 131(94.2)                           | 8(5.8)                           | 492(78.0)   | 306(62.2)                           | 186(37.8)                        |
| MSKCC nomogram, 12% cutoff         | 162(25.7)   | 152(93.8)                           | 10(6.2)                          | 469(74.3)   | 285(60.8)                           | 184(39.2)                        |

LNI, lymph node invasion; ePLND, extended pelvic lymph node dissection.

PCa patients (18). Thus, we developed and internally validated a novel nomogram predicting LNI specifically based on Chinese PCa patients treated with RP and ePLND and compared it with the three classical models, the Briganti 2012, Briganti 2017 and MSKCC nomograms.

When using our patients to externally validate the three well-established preoperative models (the Briganti 2012, Briganti 2017 and MSKCC nomograms), the AUCs for predicting LNI were substantially lower than those of the cohorts based on which the nomograms were developed. The predictive accuracy of these models was unsatisfactory for application in Chinese settings (Table 3). The LNI was 8.3%, 12.0% and 3.7% in the cohorts used for developing the Briganti 2012, Briganti 2017 and MSKCC models, respectively. The LNI in our cohort was 30.7% because the patients had a higher proportion of unfavorable tumor characteristics (4, 9). The performance of the Briganti 2017 (with 12% of LNI), Briganti 2019 (with 12.5% of LNI) and MSKCC (with 3.7% of LNI) nomograms in a recent multicenter cohort (with 24.5% of LNI) was also unsatisfactory (19). These findings suggest that the accuracy of the developed nomograms for predicting LNI differs in cohorts with different PCa grades and stages.

Our SYSUCC model showed better AUC (83%) and net benefit than three well-established Briganti 2012, Briganti 2017, and MSKCC nomograms (Figure 2). We attribute this to two new parameters our model updates, compared with the three classical nomograms. First, the results of our univariable analyses show that detailed biopsy characteristics, such as the maximum percentage of single core involvement with highest-grade PCa, which represents a predictor of LNI. Several studies also found out the association between variables that can be considered as a proxy of pathologic tumor volume and the risk of adverse prognosis in PCa patients (20, 21). Meanwhile, after the

inclusion of this covariates, the multivariable model 2 shows better improved the accuracy in predicting LNI compared with the base model including PSA, clinical stage, biopsy gleason grade group (Table 1, model 2 vs model 1). Besides, taking percentage of cores with clinically significant cancer (defined as grade group  $\geq 2$ ) on systematic biopsy into consideration can increase the accuracy of our nomogram. The main reason has been the better prognosis associated with Gleason grade group 1 cancer and the more aggressive behavior with Gleason grade group  $\geq 2$  cancer (12). One large multi-institutional study demonstrated that a pure Gleason grade group 1 cancer lacks the potential to metastasize to pelvic lymph nodes (22). Therefore, availability of the novel model would improve the predictive accuracy and reduce overestimation of the risk of LNI compared with the three previous models. For example, the calculated risk of LNI in a patient with preoperative PSA 15 ng/ml, T1c, maximum percentage of single core involvement with highest-grade disease 30%, grade group 3 disease in one core, and grade group 1 disease in five out of 12 cores would be higher than 5% according to the Briganti 2012 nomogram, 7% according to the Briganti 2017 nomogram and 2% according to the MSKCC nomogram respectively. This patient should be considered for an ePLND according to the EAU-ESTRO-SIOG or NCCN guidelines. However, the results of our model show that this patient would have a risk of LNI lower than 5% and an ePLND could be spared.

Currently, there is no consensus on an optimal nomogram cutoff for determining patients who would benefit most from ePLND. The 2022 NCCN guidelines recommended a 2% cutoff value for the MSKCC nomogram that allows 47.7% of patients to be spared an ePLND at the cost of missing 12.1% of patients who harbored LNI. Further, Table 3 shows that no patients could avoid PLND in our Chinese cohort. The Briganti 2012 and

Briganti 2017 also demonstrated comparatively poor performance when using the cutoff the authors recommended, indicating that these cutoffs might not be suitable for Chinese PCa patients. The influence of ethnic differences in the behavior of PCa was reported, and the study population might be a crucial factor in the predictive accuracy of these models (18). Therefore, we had to reevaluate the cutoff value when using the predictive model for a Chinese cohort. We believe the percentage of avoidance should be as high as possible based on a low omission rate. Using a 12% cutoff in our novel model, 189 (30%) patients could avoid ePLND, missing only 9 patients who harbored LNI (4.8%), which is appropriate.

This study had some limitations. First, since this was a single-center study, the findings cannot be generalized to other Chinese institutions. Second, external validation is still needed to confirm the validity of our model for other cohorts. Third, the clinical T stage based on digital rectal examination was used. It has been reported that multiparametric magnetic resonance imaging (MRI) based T stage might improve the accuracy of the established models for LNI prediction (8), despite the sensitivity of multiparametric MRI for predicting LNI being about 22.4% (23). Fourth, PSMA-PET-CT was not incorporated into the novel model. The addition of PSMA-PET-CT to the available nomograms (Briganti 2012, Briganti 2017, and MSKCC) was reported to improve the accuracy of the established models for predicting LNI (18), despite the sensitivity of preoperative PSMA-PET/CT for predicting LNI was reported to be <50% (24–26), and PSMA-PET/CT tended to especially miss small lymph node metastases (<5 mm) (27).

Despite these limitations, the proposed SYSUCC model could be regarded as the most appropriate scoring tool for estimating LNI in Chinese PCa patients undergoing RP and judging their need for ePLND. However, further validation is required to confirm these observations.

## 5 Conclusion

The performance of the Briganti 2012, Briganti 2017 and MSKCC nomograms in Chinese patients was unsatisfactory. Thus, the SYSUCC model was established and internally validated for predicting LNI in Chinese PCa patients and promisingly demonstrated that with a cutoff of 12%, ePLND could be potentially avoided in ~30% of patients at the cost of missing 4.8% of LNI. Besides, based on our novel nomogram, we have set up a website that can easily calculate the risk of LNI. (<http://www.sysucc-pca-lni-nomograms.com>).

## Data availability statement

The datasets presented in this article are not readily available because of the data sharing policy and procedures of the institution and groups who conducted the original study. Requests to access the datasets should be directed to the corresponding authors.

## Ethics statement

The studies involving human participants were reviewed and approved by the institutional review board (IRB) and the ethical committee of Sun Yat-sen University Cancer Center. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

## Author contributions

Writing original draft: ZL YXH; data curation: DWZ, XL; study design and methodology: YLP, YHL and FJZ; statistical analysis and data visualization: XL, YXH, and DWZ; project conceptualization: DWZ, ZSW, XYZ, YX, JWW and YXL; project execution, supervision, and administration: YH L and FJZ.

## Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

## Supplementary material

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fonc.2023.1186319/full#supplementary-material>



## References

- Hartwell H, Ruben F, Alan D, Thomas AS, Patrick CW. *Campbell's urology*. 4th ed. London: W. B. Saunders (1979) p. 2315–8.
- Engel J, Bastian PJ, Baur H, Beer V, Chaussy C, Gschwend JE, et al. Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer. *Eur Urol* (2010) 57:754–61. doi: 10.1016/j.eururo.2009.12.034
- Briganti A, Larcher A, Abdollah F, Capitanio U, Gallina A, Suardi N, et al. Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. *Eur Urol* (2012) 61:480–7. doi: 10.1016/j.eururo.2011.10.044
- Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. *CA Cancer J Clin* (2021) 71:7–33. doi: 10.3322/caac.21654
- Memorial Sloan Kettering cancer center. *dynamic prostate cancer nomogram: coefficients*. Available at: <https://www.mskcc.org/nomograms/prostate/pre-op/coefficients>.
- Gandaglia G, Fossati N, Zaffuto E, Bandini M, Dell'Oglio P, Bravi CA, et al. Development and internal validation of a novel model to identify the candidates for extended pelvic lymph node dissection in prostate cancer. *Eur Urol* (2017) 72:632–40. doi: 10.1016/j.eururo.2017.03.049
- Gandaglia G, Ploussard G, Valerio M, Mattei A, Fiori C, Fossati N, et al. A novel nomogram to identify candidates for extended pelvic lymph node dissection among patients with clinically localized prostate cancer diagnosed with magnetic resonance imaging-targeted and systematic biopsies. *Eur Urol* (2019) 75:506–14. doi: 10.1016/j.eururo.2018.10.012
- Draulans C, Everaerts W, Isebaert S, Van Bruwaene S, Gevaert T, Oyen R, et al. Development and external validation of a multiparametric magnetic resonance imaging and international society of urological pathology based add-on prediction tool to identify prostate cancer candidates for pelvic lymph node dissection. *J Urol* (2020) 203:713–8. doi: 10.1097/JU.0000000000000652
- Ma C-G, Ye D-W, Li C-L, Zhou F-J, Yao X-D, Zhang S-L, et al. Epidemiology of prostate cancer from three centers and analysis of the first-line hormonal therapy for the advanced disease. *Chin J Surg* (2008) 46(12):921–5.
- Gandaglia G, De Lorenzis E, Novara G, Fossati N, De Groot R, Dovey Z, et al. Robot-assisted radical prostatectomy and extended pelvic lymph node dissection in patients with locally-advanced prostate cancer. *Eur Urol* (2017) 71:249–56. doi: 10.1016/j.eururo.2016.05.008
- Fossati N, Sjoberg DD, Capitanio U, Gandaglia G, Larcher A, Nini A, et al. Extended pelvic lymph node dissection in patients with prostate cancer previously treated with surgery for lower urinary tract symptoms. *BJU Int* (2015) 116:366–72. doi: 10.1111/bju.12912
- Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, Magi-Galluzzi C, et al. A contemporary prostate cancer grading system: a validated alternative to the Gleason score. *Eur Urol* (2016) 69:428–35. doi: 10.1016/j.eururo.2015.06.046
- Magi-Galluzzi C, Montironi R, Epstein JI. Contemporary Gleason grading and novel grade groups in clinical practice. *Curr Opin Urol* (2016) 26:488–92. doi: 10.1097/MOU.0000000000000320
- von Bodman C, Godoy G, Chade DC, Cronin A, Tafe LJ, Fine SW, et al. Predicting biochemical recurrence-free survival for patients with positive pelvic lymph nodes at radical prostatectomy. *J Urol* (2010) 184:143–8. doi: 10.1016/j.juro.2010.03.039
- Boorjian SA, Thompson RH, Siddiqui S, Bagniewski S, Bergstralh EJ, Karnes RJ, et al. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. *J Urol* (2007) 178:864–70. doi: 10.1016/j.juro.2007.05.048
- Briganti A, Blute ML, Eastham JH, Graefen M, Heidenreich A, Karnes JR, et al. Pelvic lymph node dissection in prostate cancer. *Eur Urol* (2009) 55:1251–65. doi: 10.1016/j.eururo.2009.03.012
- Ploussard G, Briganti A, de la Taille A, Haese A, Heidenreich A, Menon M, et al. Pelvic lymph node dissection during robot-assisted radical prostatectomy: efficacy, limitations, and complications—a systematic review of the literature. *Eur Urol* (2014) 65:7–16. doi: 10.1016/j.eururo.2013.03.057
- Song C, Ro JY, Lee MS, Hong SJ, Chung BH, Choi HY, et al. Prostate cancer in Korean men exhibits poor differentiation and is adversely related to prognosis after radical prostatectomy. *Urology* (2006) 68:820–4. doi: 10.1016/j.urology.2006.04.029
- Meijer D, van Leeuwen PJ, Roberts MJ, Siriwardana AR, Morton A, Yaxley JW, et al. External validation and addition of prostate-specific membrane antigen positron emission tomography to the most frequently used nomograms for the prediction of pelvic lymph-node metastases: an international multicenter study. *Eur Urol* (2021) 80:234–42. doi: 10.1016/j.eururo.2021.05.006
- Antonelli A, Vismara Fugini A, Tardanico R, Giovanessi L, Zambolin T, Simeone C. The percentage of core involved by cancer is the best predictor of insignificant prostate cancer, according to an updated definition (tumor volume up to 2.5 cm<sup>3</sup>): analysis of a cohort of 210 consecutive patients with low-risk disease. *Urology* (2014) 83:28–32. doi: 10.1016/j.urology.2013.07.056
- Chen DJ, Falzarano SM, McKenney JK, Przybycyn CG, Reynolds JP, Roma A, et al. Does cumulative prostate cancer length (CCL) in prostate biopsies improve prediction of clinically insignificant cancer at radical prostatectomy in patients eligible for active surveillance? *BJU Int* (2015) 116:220–9. doi: 10.1111/bju.12880
- Ross HM, Kryvenko ON, Cowan JE, Simko JP, Wheeler TM, Epstein JI. Do adenocarcinomas of the prostate with Gleason score (GS) ≤6 have the potential to metastasize to lymph nodes? *Am J Surg Pathol* (2012) 36:1346–52. doi: 10.1097/PAS.0b013e3182556dcd
- Franklin A, Yaxley WJ, Raveenthiran S, Coughlin G, Gianduzzo T, Kua B, et al. Histological comparison between predictive value of preoperative 3-T multiparametric MRI and (68) Ga-PSMA PET/CT scan for pathological outcomes at radical prostatectomy and pelvic lymph node dissection for prostate cancer. *BJU Int* (2021) 127:71–9. doi: 10.1111/bju.15134
- Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. *Lancet* (2020) 395:1208–16. doi: 10.1016/S0140-6736(20)30314-7
- Meijer D, de Barros HA, van Leeuwen PJ, Bodar YJL, van der Poel HG, Donswijk ML, et al. The predictive value of preoperative negative prostate specific membrane antigen positron emission tomography imaging for lymph node metastatic prostate cancer. *J Urol* (2021) 205:1655–62. doi: 10.1097/JU.0000000000001592
- Amiel T, Würnschimmel C, Heck M, Horn T, Nguyen N, Budäus L, et al. Regional lymph node metastasis on prostate specific membrane antigen positron emission tomography correlates with decreased biochemical recurrence-free and therapy-free survival after radical prostatectomy: a retrospective single-center single-arm observational study. *J Urol* (2021) 205:1663–70. doi: 10.1097/JU.0000000000001596
- Linxweiler J, Spreng J, Cascetta K, Prylukhin A, Hölter S, Zeuschner P, et al. Robotic salvage lymph node dissection in recurrent prostate cancer: lessons learned from 68 cases and implications for future clinical management. *J Urol* (2021) 206:88–96. doi: 10.1097/JU.0000000000001697